One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Denmark once again led the EU in 2024 with the largest public budget surplus relative to GDP. According to new figures from Danmarks Statistik, the country recorded a surplus of DKK 133.3 billion last ...

Drugs such as Ozempic cut our craving for food. But they can’t control our hunger for all the good things in life.

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

COPENHAGEN, Denmark, April 24, 2025 /PRNewswire/ -- Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences ...

Antag Therapeutics, a biopharmaceutical company pioneering novel treatments for obesity, has appointed three new hires to support the Company’s next phase of growth following the recent initiation of ...

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal Clinical Pharmacology Scientist at Novo Nordisk, having led several global ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 15 unusual trades. Delving into the details, we found 46% of ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...